261 related articles for article (PubMed ID: 14534919)
21. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
Parkinson Study Group
Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
[TBL] [Abstract][Full Text] [Related]
22. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
Parkinson Study Group CALM Cohort Investigators
Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
[TBL] [Abstract][Full Text] [Related]
23. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study.
Pinter MM; Pogarell O; Oertel WH
J Neurol Neurosurg Psychiatry; 1999 Apr; 66(4):436-41. PubMed ID: 10201413
[TBL] [Abstract][Full Text] [Related]
24. Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease.
Bara-Jimenez W; Dimitrova T; Sherzai A; Favit A; Mouradian MM; Chase TN
Mov Disord; 2004 Oct; 19(10):1183-6. PubMed ID: 15390018
[TBL] [Abstract][Full Text] [Related]
25. Pramipexole extended release in Parkinson's disease.
Hametner EM; Seppi K; Poewe W
Expert Rev Neurother; 2011 Sep; 11(9):1229-34. PubMed ID: 21864066
[TBL] [Abstract][Full Text] [Related]
26. Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease.
Rascol O; Barone P; Hauser RA; Mizuno Y; Poewe W; Schapira AH; Salin L; Sohr M; Debieuvre C;
Mov Disord; 2010 Oct; 25(14):2326-32. PubMed ID: 20669265
[TBL] [Abstract][Full Text] [Related]
27. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group.
Shannon KM; Bennett JP; Friedman JH
Neurology; 1997 Sep; 49(3):724-8. PubMed ID: 9305331
[TBL] [Abstract][Full Text] [Related]
29. Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on Parkinsonian tremor.
Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG
Mov Disord; 2003 Nov; 18(11):1324-31. PubMed ID: 14639675
[TBL] [Abstract][Full Text] [Related]
30. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.
Dooley M; Markham A
Drugs Aging; 1998 Jun; 12(6):495-514. PubMed ID: 9638397
[TBL] [Abstract][Full Text] [Related]
31. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
32. Impact of pramipexole on the onset of levodopa-related dyskinesias.
Constantinescu R; Romer M; McDermott MP; Kamp C; Kieburtz K;
Mov Disord; 2007 Jul; 22(9):1317-9. PubMed ID: 17534955
[TBL] [Abstract][Full Text] [Related]
33. Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations.
Marras C; Lang A; Krahn M; Tomlinson G; Naglie G;
Mov Disord; 2004 Jan; 19(1):22-8. PubMed ID: 14743356
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic and pharmacodynamic comparison of ropinirole 24-hour prolonged release and ropinirole immediate release in patients with Parkinson's disease.
Tompson D; Oliver-Willwong R
Clin Neuropharmacol; 2009; 32(3):140-8. PubMed ID: 18978485
[TBL] [Abstract][Full Text] [Related]
35. Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose.
Pahwa R; Koller WC; Trosch RM; Sherry JH;
J Neurol Sci; 2007 Jul; 258(1-2):137-43. PubMed ID: 17466338
[TBL] [Abstract][Full Text] [Related]
36. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome.
Antonini A; Isaias IU; Canesi M; Zibetti M; Mancini F; Manfredi L; Dal Fante M; Lopiano L; Pezzoli G
Mov Disord; 2007 Jun; 22(8):1145-9. PubMed ID: 17661426
[TBL] [Abstract][Full Text] [Related]
37. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
[TBL] [Abstract][Full Text] [Related]
38. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease.
Hauser RA; Holford NH
Mov Disord; 2002 Sep; 17(5):961-8. PubMed ID: 12360545
[TBL] [Abstract][Full Text] [Related]
39. Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors.
Talati R; Reinhart K; Baker W; White CM; Coleman CI
Parkinsonism Relat Disord; 2009 Aug; 15(7):500-5. PubMed ID: 19167259
[TBL] [Abstract][Full Text] [Related]
40. Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study.
Schapira AH; Albrecht S; Barone P; Comella CL; McDermott MP; Mizuno Y; Poewe W; Rascol O; Marek K
Mov Disord; 2010 Aug; 25(11):1627-32. PubMed ID: 20544810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]